UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety
December 16 2019 - 8:59AM
Business Wire
UCB Implements Accenture’s technology platform,
INTIENT™ Pharmacovigilance
Accenture (NYSE:ACN) and UCB, a global biopharmaceutical
company, have collaborated to build a safety solution based on
Accenture’s INTIENT™ Pharmacovigilance to accelerate processing of
individual patient safety case reports. This will help UCB uncover
patient safety impacts from existing treatments and better manage
the risks of new drugs and services.
Accenture’s INTIENT Pharmacovigilance leverages artificial
intelligence to collect, manage and learn from UCB’s structured and
unstructured source data within pharmacovigilance, which monitors
the effects of drugs during clinical trials and after they have
been cleared by regulators for use.
INTIENT Pharmacovigilance improves the flow of data, making
pharmacovigilance case processing faster, less costly and more
consistent. An Accenture Life Sciences operations team is managing
case processing augmented by the platform for UCB, allowing UCB’s
case processing team to focus on value-add activities such as
medical assessment and targeted follow up, helping them uncover
insights into emerging trends, potential compliance issues and
adverse events.
This solution embeds real-time artificial intelligence, machine
learning and robotic process automation into the data management
process — from gathering initial patient information and subsequent
inputs to regulatory reporting. This platform further improves
accuracy and consistency in reporting, supports a more timely
discovery of potential adverse events, while also supporting
compliance with data privacy Good Pharmacovigilance Practice (GPvP)
productive system requirements and policies.
“The patients who benefit from our products are UCB’s number one
priority,” said Kristof Huysentruyt, senior director and head of
safety data management and systems at UCB Pharma. “Accenture
INTIENT Pharmacovigilance will help us rapidly process data to
identify potential events or issues, while reducing the time and
cost needed to deliver a higher level of patient safety. This
solution helps us walk the talk of being patient-driven.”
One of the realities that is driving the need for INTIENT is the
many variable forms of data being managed within the life sciences
industry, including both structured and unstructured data, as well
as the vast number of data sources. Structured data is highly
organized and formatted in a way that is easily searchable in
related databases; however, unstructured data has no pre-defined
format or organization, making it much more difficult to collect,
process and analyze — and to derive scientific insights.
“UCB is demonstrating its industry leadership and commitment to
patient safety through the implementation of INTIENT
Pharmacovigilance. With variable case types and sources and complex
regulatory changes varying by geographic region, pharmaceutical and
biotechnology executives can use INTIENT to support their data
security, efficiency and analysis objectives,” said Kevin Julian, a
senior managing director in the Accenture Life Sciences practice.
“Most importantly, the platform and the services provided around it
can help advance the discovery and development of new patient
treatments by unlocking information that otherwise might be trapped
in silos, enabling unfettered access to actionable insights and
improved collaboration across the life sciences enterprise.”
INTIENT Pharmacovigilance is a part of Accenture INTIENT, a
platform introduced in May 2019 that will improve the continuity
and flow of data across life sciences enterprises. Learn more about
Accenture INTIENT.
About Accenture
Accenture is a leading global professional services company,
providing a broad range of services and solutions in strategy,
consulting, digital, technology and operations. Combining unmatched
experience and specialized skills across more than 40 industries
and all business functions — underpinned by the world’s largest
delivery network — Accenture works at the intersection of business
and technology to help clients improve their performance and create
sustainable value for their stakeholders. With 492,000 people
serving clients in more than 120 countries, Accenture drives
innovation to improve the way the world works and lives. Visit us
at www.accenture.com.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global
biopharmaceutical company focused on the discovery and development
of innovative medicines and solutions to transform the lives of
people living with severe diseases of the immune system or of the
central nervous system. With 7 500 people in approximately 40
countries, the company generated revenue of € 4.6 billion in 2018.
UCB is listed on Euronext Brussels (symbol: UCB). Follow us on
Twitter: @UCB_news.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191216005013/en/
Lara Wozniak Accenture +1 858 252 8208
lara.wozniak@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Sep 2023 to Sep 2024